Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
GATA2 encodes a zinc-finger transcription factor essential for hematopoietic and lymphatic development. Heterozygous loss-of-function variants in GATA2 cause Emberger syndrome (deafness-lymphedema-leukemia syndrome), an autosomal dominant disorder characterized by primary lymphedema, cytopenias, immunodeficiency, and predisposition to myelodysplasia and acute myeloid leukemia (PMID:21892158). Incomplete penetrance and variable expressivity are observed, with epistaxis, recurrent warts, onychomycosis, and severe infections frequently reported (PMID:28271814). Early recognition is critical to guide surveillance and therapeutic interventions, including hematopoietic stem cell transplantation.
Inheritance is autosomal dominant via haploinsufficiency. The recurrent null variant c.130G>T (p.Glu44Ter) segregated with disease in three affected siblings and two asymptomatic carriers in a single pedigree, illustrating incomplete penetrance (PMID:28271814). A broader allelic series of eight distinct GATA2 mutations—including nonsense, frameshift, and splice-site changes—was identified in unrelated families, collectively accounting for >65 probands with Emberger syndrome (PMID:21892158). Regulatory and deep-intronic variants further expand the mutational spectrum.
Segregation analyses demonstrate co-segregation of pathogenic GATA2 alleles with disease in at least 3 affected relatives per family, supporting a definitive autosomal dominant inheritance pattern. Additional segregation in eight pedigrees in the initial series reinforces the pathogenicity of loss-of-function variants (PMID:21892158).
Functional studies corroborate the haploinsufficiency mechanism. Conditional Gata2 deletion in mice abolishes lymphatic vessel valve development and induces lymphedema analogous to human Emberger syndrome (PMID:26214525). Cross-sectional analyses of 24 GATA2-mutant patients reveal progressive DCML (dendritic cell, monocyte, B and NK cell) deficiency and elevated FLT3 ligand, mirroring human immunodeficiency and bone marrow failure (PMID:24345756). A germline intronic enhancer mutation (c.1017+572C>T) selectively impairs stress-induced hematopoietic regeneration while sparing developmental hematopoiesis, elucidating a novel regulatory mechanism (PMID:30620726).
No substantive conflicting evidence has been reported, although asymptomatic carriers indicate that additional genetic or epigenetic modifiers influence penetrance (PMID:28271814).
Integrating robust genetic segregation, a diverse mutational spectrum, and compelling in vivo and in vitro functional concordance, the GATA2–Emberger syndrome association is classified as definitive. Genetic testing for GATA2 variants has direct clinical utility for early diagnosis, family screening, and guiding hematopoietic stem cell transplantation decisions. Key Take-home: Germline GATA2 haploinsufficiency definitively causes Emberger syndrome, enabling precise molecular diagnosis and tailored clinical management.
Gene–Disease AssociationDefinitiveOver 65 affected individuals across multiple unrelated families; autosomal dominant segregation in ≥8 pedigrees; concordant loss-of-function mechanism demonstrated Genetic EvidenceStrongMultiple independent allelic variants including null, frameshift, splice-site, and regulatory mutations segregate with disease in >8 families Functional EvidenceStrongIn vivo Gata2 mouse models recapitulate lymphatic and hematopoietic defects; in vitro assays demonstrate impaired transcriptional and enhancer activity of pathogenic variants |